

# Kristina B Emdal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7079914/publications.pdf>

Version: 2024-02-01

9  
papers

412  
citations

1163117  
8  
h-index

1588992  
8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1111  
citing authors

#	ARTICLE	IF	CITATIONS
1	Causal integration of multi-omics data with prior knowledge to generate mechanistic hypotheses. <i>Molecular Systems Biology</i> , 2021, 17, e9730.	7.2	78
2	Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites. <i>Cell</i> , 2019, 179, 543-560.e26.	28.9	65
3	Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation. <i>Science Signaling</i> , 2015, 8, ra40.	3.6	64
4	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 354-369.	9.4	62
5	Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. <i>Nature Communications</i> , 2018, 9, 4904.	12.8	62
6	Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. <i>Science Signaling</i> , 2018, 11, .	3.6	33
7	Characterization of <i>In Vivo</i> Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2572-2585.	4.1	26
8	Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 88-101.	4.1	17
9	Molecular switches in signaling networks as a mechanism of action for oncogenic mutations in proximity of tyrosine residues. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1692643.	0.7	0